Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Lupus Erythematosus, Subacute Cutaneous: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Lupus Erythematosus, Subacute Cutaneous: 1 US clinical trial tracked, none currently recruiting.

Lupus Erythematosus, Subacute Cutaneous is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Bristol-Myers Squibb, running 1 of these trials.

Enrollment posture brief

Registry condition lupus-erythematosus-subacute-cutaneous

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Lupus Erythematosus, Sub (th…0%
Open-enrollment share among volume-matched conditions near Lupus Erythematosus, Subacute Cutaneous

Lupus Erythematosus, Subacute Cutaneous has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Lupus Erythematosus, Subacute Cutaneous on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Lupus Erythematosus, Subacute Cutaneous is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Lupus Erythematosus, Subacute Cutaneous records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Deucravacitinib Drug
1 trials
Placebo Drug
1 trials

US sites by state

Facility locations filed on Lupus Erythematosus, Subacute Cutaneous trials. A trial with sites in several states counts in each.

South Carolina 1 trials
Oklahoma 1 trials
Ohio 1 trials
New York 1 trials
North Carolina 1 trials
Missouri 1 trials
Michigan 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Lupus Erythematosus, Subacute Cutaneous page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Lupus Erythematosus, Subacute Cutaneous trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Bristol-Myers Squibb sponsors the most Lupus Erythematosus, Subacute Cutaneous trials on record, review their full trial history before evaluating a specific study. See Bristol-Myers Squibb's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lupus Erythematosus, Subacute Cutaneous condition card totals 1 registered trials; most-linked intervention Deucravacitinib; top US site state South Carolina. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.